期刊文献+

替吉奥联合多西他赛治疗晚期胃癌的疗效观察 被引量:1

To observe the curative effect of S-1 combined with docetaxel in the treatment of advanced gastric cancer
下载PDF
导出
摘要 目的观察评价替吉奥联合多西他赛化疗治疗晚期胃癌的近期疗效和毒副反应。方法选择我院2008年1月—2013年6月收治的24例无法手术及放疗的晚期胃癌患者,给予替吉奥40 mgbid/m^2d1-14,多西他赛40 mg/m^2d1联合化疗,每21 d为1个周期,每完成2个周期评价疗效。每个周期化疗后评价毒副反应。结果 24例总有效率为41.7%,疾病控制率70.8%。主要毒副反应为骨髓抑制、胃肠道反应等,均为轻、到中度。结论替吉奥联合多西他赛治疗晚期胃癌疗效确切,毒副反应较低,值得临床推广及进一步研究。 Objective Objective To observe the efficacy and toxicity 0f docetaxel and S-1 combined evaluation of chemotherapy in the treatment of advanced gastric cancer.Methods In our hospital from 2008 January to 2013 June were treated 24 cases of no operation and radiotherapy in patients with advanced gastric cancer, give 40mg bid/m2 dl-14 40mg/m2 s-l, docetaxel chemotherapy combined with D1, every 21 d for 1 cycles, each completed 2 cycles efficacy evaluation. Toxicity evaluation of each cycle of chemotherapy.Results Of the 24 cases, the total effective rate was 41.7%, disease control rate of 70.8%.The main side effects were bone marrow suppression, gastrointestinal reactions were mild to moderate.Conclusion S-1 combined with docetaxel exact curative effect in the treatment of advanced gastric cancer, toxicity is low, is worth the clinical promotion and further research.
机构地区 南通市肿瘤医院
出处 《中国卫生产业》 2013年第30期22-23,共2页 China Health Industry
关键词 晚期胃癌 替吉奥 多西他赛 联合化疗 S-l Advanced gastric cancer Docetaxel Combined chemotherapy
  • 相关文献

参考文献5

  • 1汤钊猷.现代肿瘤学[M].上海:复旦.大学出版社,2003:696~729. 被引量:1
  • 2Takahashi I,Kakeji Y,Emi Y,et al.S-1 in the treatment of ad-vanced and recurrent gastric cancer:current state and futureprospects[J].Gastric Cancer,2003,6 Suppl 1:28-33. 被引量:1
  • 3Zang DY,Lee BH,Park HC,et al.Phase Ⅱ study with oxaliplatin and S-I for patients with metastatic colorectal cancer[J].AnnOncol,2009,20:892-896. 被引量:1
  • 4Makt-Manino M,Malnino R.Clinical studies of three oral prodrugs of 5-fluorouracil(capecitabine,UFT,S-l):a review[J].Oncologist,2002,7:288-323. 被引量:1
  • 5秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268

二级参考文献17

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2Moiseyenko VM,Ajani JA,Tjulandin SA,et al.Final results of a randomized controlled phase Ⅲ trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F)to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2005,23:Abstract 4002. 被引量:1
  • 3Al-Batran S,Hartmann J,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP)[J].J Clin Onc,Proc Am Soc Clin Oncol,2006,24:Abstract 4016. 被引量:1
  • 4Bugat R.Irinotecan in the treatment of gastric cancer[J].Ann Oncol,2003,14(Suppl 2):37 -40. 被引量:1
  • 5Bouche O,Raoul JL,Bonnetain F,et al.Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803[ J].J Clin Oncol,2004,22 (21):4319-4328. 被引量:1
  • 6Fazio N,Zampino G,Nol F,et al.Irinotecan combined with in fusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemo therapy[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4146a. 被引量:1
  • 7Peeters M,Van Laethem JL,Baert F,et al.Phase Ⅱ study of irinotecan+ 5FU/FA for patients with previously treated ad vanced gastric cancer[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4076a. 被引量:1
  • 8Bamias A,Papamichael D,Syrigos K,et al.Phase Ⅱ study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer[J].J Chemother,2003,15(3):275 -281. 被引量:1
  • 9Giuliani F,Maiello E,Molica S,et al.Irinotecan (CPT-11)and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients.A phase Ⅱ study of the Gruppo Oncologico dell Italia Meridionale (GOIM)[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4235. 被引量:1
  • 10Shah M A,Ramanathan RK,Ilson D,et al.Final results of a multicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2006,24 (18S):Abstract 4020. 被引量:1

共引文献267

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部